CN102188409A - 速溶剂型的包装和分配 - Google Patents
速溶剂型的包装和分配 Download PDFInfo
- Publication number
- CN102188409A CN102188409A CN201110060549.6A CN201110060549A CN102188409A CN 102188409 A CN102188409 A CN 102188409A CN 201110060549 A CN201110060549 A CN 201110060549A CN 102188409 A CN102188409 A CN 102188409A
- Authority
- CN
- China
- Prior art keywords
- pouch
- film
- atenuator region
- dosage form
- layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 title claims abstract description 64
- 238000004806 packaging method and process Methods 0.000 title abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 26
- 239000013543 active substance Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 17
- 238000012856 packing Methods 0.000 claims description 16
- 238000007789 sealing Methods 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 5
- 239000002195 soluble material Substances 0.000 claims description 3
- 239000004821 Contact adhesive Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000010408 film Substances 0.000 description 85
- 239000000203 mixture Substances 0.000 description 23
- 239000000463 material Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- -1 hydroxypropyl Chemical group 0.000 description 9
- 230000004888 barrier function Effects 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 238000009827 uniform distribution Methods 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940034982 antineoplastic agent Drugs 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000003208 anti-thyroid effect Effects 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940043671 antithyroid preparations Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical compound OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- NOHUXXDTQJPXSB-UHFFFAOYSA-N 2-acetyloxybenzoic acid;2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 NOHUXXDTQJPXSB-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 108010055615 Zein Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940003558 aggrenox Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003555 analeptic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000000228 antimanic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 229940018557 citraconic acid Drugs 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000002196 ecbolic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000009342 ragweed pollen Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229940071440 soy protein isolate Drugs 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000001349 uterorelaxant effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
- A61J3/078—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of wafers or cachets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B11/00—Wrapping, e.g. partially or wholly enclosing, articles or quantities of material, in strips, sheets or blanks, of flexible material
- B65B11/50—Enclosing articles, or quantities of material, by disposing contents between two sheets, e.g. pocketed sheets, and securing their opposed free margins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B5/00—Packaging individual articles in containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, jars
- B65B5/06—Packaging groups of articles, the groups being treated as single articles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B25/00—Packaging other articles presenting special problems
- B65B25/06—Packaging slices or specially-shaped pieces of meat, cheese, or other plastic or tacky products
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mechanical Engineering (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Preparation (AREA)
- Bag Frames (AREA)
- Wrappers (AREA)
- Packages (AREA)
Abstract
公开了速溶剂型的包装和分配。涉及一种口服剂量输递载体,它包含含有均匀分布的活性成分的可食用膜,其中所述膜含有通过一个或多个弱化区域连接的可释放的剂量单位,这些弱化区域使得所述剂量单位可从所述膜中分离。
Description
本申请是2003.07.22提交的申请号为03822424.0,题为“速溶剂型的包装和分配”的分案申请。
技术领域
本发明涉及可食用的、薄的、水溶性的速溶剂型的贮存和分配的装置和方法。
背景技术
近来水溶性膜作为口气清新剂的形式很受欢迎。这些膜通常包含口气清新制剂在聚合物膜中。这些膜体积小、方便,这使得它们很受欢迎。
但是,这些膜和它们现有的包装有许多缺点。膜本身常常太薄难以支持其他活性成分,如药物活性成分。另外,包装不能提供对空气/潮湿的有效屏障。结果只膜经常会干燥,变得太脆难以使用。而且,在膜被置于包装中时,它们常常是堆叠的,经常与周围的膜相互粘连。因此,当人试图从包装中拿出一张膜时,可能会无意间拿出两张或更多。
因此需要提供膜和包括能够屏障可干扰膜产品和膜所包含的活性成分的质量的潮湿、空气和光线的包装。该膜不仅能够支持口气清新剂的活性成分,而且还支持药物产品就更理想了。还需要提供分配该膜的方法,其中,一次只可取出所需数量的膜。
发明概述
本发明提供一种口服剂量输递载体,其包含薄片样结构的可食用膜,其中,所述膜含有通过一个或多个弱化区域连接的可释放的剂量单位,这些弱化区域使得所述剂量单位可从所述膜中分离。这些弱化区域包含可离断该膜的穿孔或刻痕构造较好。单个剂量单位在其组合物是均匀的并包括可均匀分布的活性成分,如药物、美容品或生物活性制剂等更好。
本发明还提供了用于贮存和分配可食用薄片样速溶剂型的包装,如膜。本发明包括放置薄片样剂型的小袋。该小袋包括顶层和底层,在边缘封口,它们中间的空间可贮存薄片样剂型。该小袋也可包括再封口装置以防止另外的光线、潮湿和/或空气的影响。该再封口装置可包括粘合包被、机械关闭装置,就像再封口塑料袋和其他类似再封口装置中可见的装置。
虽然各种膜形成技术可被用于制备本发明的薄片样速溶剂型,本发明还包括制备可食用剂型的独特方法,这使得组合物成分的均匀状态可通过膜均匀分布。该方法详细记载在题为“非自聚集的均匀异质性薄膜和用该薄膜制备的药物输递系统(Thin Film With Non-Self-Aggregating Uniform Heterogeneity and Drug Delivery Systems Made Therefrom)”的待定美国专利申请No.10/074,272中,该文件被全文并入本文。该方法可提供有基本相同量活性成分的一致的剂型并可以包括各种活性成分,包括药物成分。
本发明的另一方面提供了可食用薄片样速溶剂型的贮存方法。该方法包括首先制备包含一个或多个单位剂量的活性成分的薄片样剂型。该薄片可通过各个单位或部分之间的弱化区域来分离,分成代表单个剂量单位或剂量单位预先确定部分的基本相等的面积较佳。该薄片置于小袋中,该小袋包括顶层和底层,包括屏障层更佳。该顶层和底层在边缘封口,封口可使用粘合剂,较佳的是可热封口,对压力敏感或在室温下形成粘合的粘合剂。
本发明的另一方面提供了分配薄片样剂型的方法。首先,制备包含一种或多种剂量活性成分的薄片样剂型。随后剂型可在其中的弱化区域来分离形成单个部分或单位,分成代表上文所述单个剂量单位或剂量单位部分的基本相等的面积较佳。该薄片置于小袋中,该小袋有可包括屏障材料的顶层和底层。该小袋在边缘封口。该剂型可通过打开小袋的一部分,是边缘部分较佳,随后沿着弱化区域从薄片中分离一个或多个部分的剂型,并从袋中移出分离的一个或多个剂量单位。该小袋随后可被再封口。
本发明的第四个方面提供了一种口服剂量输递载体,其包含含有均匀分布的活性成分的可食用膜,含有通过一个或多个弱化区域连接的可释放的剂量单位,这些弱化区域使得所述剂量单位可从所述膜中分离。优选膜是自持的。优选弱化区域是穿孔的。优选弱化区域是有刻痕的。优选活性物质是药物或化妆品活性物质。优选活性物质在所述剂量单位中不超过10%。
在该方面的一个优选例中,膜包括基本水溶性材料的载体层。更优选载体层是基本连续的。更优选载体层包括与所述膜的弱化区域相应的弱化区域。
在该方面的一个优选例中,膜的表面区域包含增加表面积的空隙。优选空隙增加所述输递载体的溶解速度。优选空隙选自穿过膜全部厚度全部厚度的空隙、穿过膜部分厚度的空隙、通过膜在有图案的模板上塑压膜形成的空隙。优选空隙是均匀的并维持活性物质均匀分布。
在本发明的第五个方面,提供了一种包含可食用膜的口服剂量输递载体,该膜含有通过一个或多个弱化区域连接的可释放的剂量单位,这些弱化区域使得所述剂量单位可从所述膜中分离。优选弱化区域包含的膜组合物少于周围区域。优选膜是自持的。优选弱化区域是穿孔的。优选弱化区域是有刻痕的。优选弱化区域比周围区域薄。优选该载体还包含活性成分。更优选活性物质是药物或化妆品活性物质。更优选活性物质是均匀分布的,其中更优选膜的表面区域包含增加表面积的空隙;甚至更优选空隙选自穿过膜全部厚度的空隙、穿过膜部分厚度的空隙、通过膜在有图案的模板上塑压膜形成的空隙,或空隙是均匀的并维持活性物质均匀分布。更优选活性物质在所述剂量单位中不超过10%。
在该方面的一个优选例中,膜包括基本水溶性材料的载体层。优选载体层是基本连续的。优选载体层包括与所述膜的弱化区域相应的弱化区域。
在本发明第四个方面的一个优选例中,该输递载体还包括一个包含顶层和底层的小袋,顶层和底层都有一个外缘,其中,所述顶层和底层在各自的外缘封口以在其中确定一个封闭的内表面,可食用膜含在所述封闭空间内。优选其中的剂型包含活性成分。优选弱化区域包括穿孔。优选弱化区域比周围区域薄。优选弱化区域在选自垂直、水平和两个方向的方向上形成一条或多条等距离的线。优选小袋是再封口的。
在本发明的第六个方面,提供了一种贮存薄片样速溶剂型的方法,包括以下步骤:
a)制备含有活性成分的薄片样剂型;
b)在所述剂型中把所述剂型限定成许多基本相等的弱化区域可分离的剂量单位;
c)制备包含顶层和底层的小袋,顶层和底层都有一个外缘;
d)把所述剂型置于所述顶层和底层之间;和
e)封闭所述小袋的外缘。
在本发明的第七个方面,提供了一种分配薄片样剂型的方法,包括以下步骤:
a)制备含有活性成分的薄片样剂型;
b)通过弱化区域把所述剂型分成基本相等面积的部分;
c)制备包含顶层和底层的小袋,所述各层的每一层有围绕所述层外周的边缘;
d)把所述剂型置于所述顶层和底层之间;
e)可分离地封闭所述小袋的所述边缘部分;
f)打开所述小袋的一部分;
g)沿着穿孔打开所述剂型的一个或多个所述部分;和
h)从所述小袋中移出所述一个或多个部分。
优选该方法还包括再封口所述小袋的步骤。还优选包括永久性地封闭所述小袋边缘余下部分的步骤。
附图简述
图1-图3是本发明的薄片样剂型的透视图。
图4是包含薄片样剂型的尚未组装的顶层和底层薄片的透视图。
图5是本发明组装后包装的透视图。
图6是可被用作包装的顶层和底层的薄片的横截面。
图7-图9a是沿着线20-20切开的包装的横截面,包括再封口边缘。
图10是沿着线20-20切开的包装的横截面,显示其中包含一种以上含活性物质的薄片。
图11是剂型的俯视图,显示了弱化区域的细节。
图12-图13是沿着线50-50切开的剂型的横截面,详细显示了弱化区域的不同结构。
图14是剂型的俯视图,显示了弱化区域的细节。
图15是弱化区域细节的侧面图。
图16-图17是包含背衬层的剂型的侧面图。
图18是膜的透视图,该膜的表面被改变以增加表面积。
图19-图21是沿着线60-60切开的横截面,显示表面改变的细节。
发明详述
本发明包括“薄片样”剂型或膜。出于本发明的目的,术语“薄片样”剂型、“薄片”和膜是指包括厚度小于约15密耳的水溶性释放系统。薄片样剂型是可食用的并含有活性成分的较佳。
水溶性速溶剂型的薄片或膜5,它可包含一种或多种剂型1,可含有弱化区域,如图1-图3所示。弱化区域的设计使得在该处应用弯曲力可使邻近单位相互分离。薄片的弱化区域2可在垂直方向或水平方向上,或两个方向上,形成直线,虽然不直的线也可被使用。弱化区域把薄片划分成代表活性物质单个剂量的部分。这些部分可有各种不同的形状和大小,包括正方形、长方形、三角形、梯形、环形、椭圆等。各条线结合来提供基本相等面积的部分较佳。每个部分代表单个剂型或剂型的预先确定部分。例如,特殊活性物质的儿童剂量可以是成人剂量的一半,或者对特定剂量需要大的膜,膜可被分离以方便使用。例如,在图2中,显示了薄片通过穿孔连接成两个部分,每个部分可以是一个剂量单位,或者整个薄片可以是单个剂量单位。
如图11-13所示,弱化区域本身可有许多不同的结构。在大体上,薄片的弱化区域是薄片上被改变使得膜部分可分离的位置。弱化区域的形成使得单个剂型是基本相同的面积较佳。在剂型包含活性物质时,分离的剂量单位是均匀的,其中,所述单个剂型在分离前后的变化小于10%较佳。弱化区域可以是允许该膜的一个部分与其余膜分离的任何构造。弱化区域的例子包括如图11所示的可在材料上形成空隙30的穿孔或刻痕区域。如图12和图13所示,空隙30a和30b分别可全部或部分穿透该膜。
在膜大小的均匀性不是关键的时候,包括该剂型不包含药物活性物质时,可使用弱化区域的其他形式。例子包括如图14所示的膜5的较窄区域32和如图15所示的厚度比周围膜小的区域34。该弱化区域的形成可通过切割膜、把膜制成预先确定的形状或把膜置于有图案的表面使膜产生特定选择的较薄区域。
上文所述弱化区域被作为膜可被分成单个剂量单位的断点。膜本身通常是柔软的,可防止剂量单位在无意间或过早地分离和破坏。但是,弱化区域使得膜被分成代表单个剂量的预先确定的部分。这种分离可以是折断、弯曲、撕扯或其他分离膜或薄片样结构的单个部分的形式。该剂型可包括沿着弱化区域的可食用墨水形成的线。这种线可作为使用者可见的“安全”指示,指明他们分离合适的剂量单位。特别在使用穿孔的剂量单位时,这可以保证使用者在合适的部位分离剂型。这可以通过用锯齿状刀状工具对膜穿孔来完成,其中可包括在切割时标记膜的可食用墨水的划线工具。还可使用形成安全线的其他方法,如印刷。
膜的表面可以是平滑的,或是变成可增加膜表面积的形式。当表面改变时,包括图18所示的空隙42或孔。这些孔可以统一的形式安排在膜上,这种形式不影响膜可包含的任何活性物质分布的均一性。空隙有增加膜表面积的效果,这会加速膜施用时的溶解时间,包括加速膜在口中的溶解速度。如图19-21所示,空隙可有各种不同的形状,可以是如图19所示的基本穿过材料厚度的空隙42a,也可是如图20-21所示的部分穿过材料厚度的空隙42b和42c。薄膜表面积的改变可用维持膜强度的形式处理,与弱化区域的改变不同。空隙的形成是通过切割膜或把膜置于模板上产生特殊形态就理想了。
如图16和17所示,薄片样剂型5可包括基本水溶性背衬层25。虽然膜可以自身支撑,第二载体层25可作为剂型5的支持层。载体层25可以是连续的,不包含图16所示的弱化区域2,或者可包含与膜5的弱化区域2相应的弱化区域2a使第二层25沿着剂型5的相应部分分离第二层,如图17所示。
本发明的可食用薄片样剂型包括水溶性聚合物。本发明可用的水溶性聚合物包括纤维物质、树胶、蛋白质、淀粉和它们的组合物。
本发明的一个优点是剂量单位或其部分可被容易地分配。例如,一种10mg剂量单位本身可包含断点部分,即穿孔部分,以使患者可以在两个不同的时间间隔分开使用需要的10mg剂量部分,或只是方便一次咽下。
纤维质物质的例子包括但不限于羧甲基纤维素、羟甲基纤维素、羟乙基纤维素、羟丙基纤维素、羟丙基甲基纤维素和它们的组合物。
水溶性树胶的例子包括阿拉伯胶、黄原胶、黄蓍胶、阿拉伯胶、角叉菜胶、瓜尔胶、刺槐豆胶、果胶、藻酸盐和它们的组合物。
聚合物材料的例子包括聚乙烯醇、聚丙烯酸、聚乙烯吡咯烷酮、聚甲丙烯酸酯、聚甲基共聚物和它们的组合物。
可用的淀粉包括胶质化的、改良的或未改良的淀粉。淀粉的来源可以各种各样并包括木薯、稻、玉米、马铃薯、小麦和它们的组合物。
可用的水溶性蛋白质聚合物包括凝胶、玉米蛋白、谷蛋白、大豆蛋白、大豆蛋白分离物、乳清蛋白、乳清蛋白分离物、酪蛋白、levin、胶原蛋白和它们的组合物。
其他水溶性聚合物包括糊精、右旋糖苷和它们的组合物,以及壳多糖、脱乙酰壳多糖(chitosin)或其组合物,以及多聚右旋糖。
本发明的薄片样剂型还包括选自化妆品制剂、药物制剂、生物活性制剂(包括抗原,如豚草花粉)及其组合物的活性成分。该活性成分可以是预定治疗的任何有效量。活性成分在本发明中可以是高负荷就更佳和有利了。例如,活性成分的量达到整体组合物重量的约60%,占整体组合物重量的0.01%到约50%较佳。
可掺入本发明的膜的活性成分包括但不限于药物、香料、香味剂、酶、防腐剂、甜味剂、着色剂、调味品、维生素和其组合物。
各种药物和药物组合物可被包括在本发明的剂型中。可用药物的例子包括ace-抑制剂、抗心绞痛药、抗心率失常药、抗哮喘药、抗胆固醇药、镇痛药、麻醉药、抗惊厥药、抗抑郁药、抗糖尿病剂、抗腹泻制剂、解毒药、抗组胺药、抗高血压药、抗炎剂、抗脂剂、抗躁狂药、抗呕吐药、抗中风药、抗甲状腺制剂、抗肿瘤药、抗病毒剂、痤疮药、生物碱类药物、氨基酸制剂、镇咳药、抗尿酸药、抗病毒药、合成代谢制剂、全身性和非全身性抗传染药、抗肿瘤药、抗帕金森综合征剂、抗风湿剂、食欲刺激剂、生物应答调节剂、血液调节剂、骨代谢调节剂、心血管剂、中枢神经系统刺激剂、胆碱脂酶抑制剂、避孕药、减充血剂、饮食补充剂、多巴胺受体激动剂、子宫内膜异位治疗剂、酶、勃起功能障碍治疗剂、致育剂、胃肠道制剂、类似疗法剂、激素、高钙血症和低钙血症治疗剂、免疫调节剂、免疫抑制剂、偏头痛制剂、晕动病治疗剂、肌肉松弛剂、肥胖治疗剂、骨质疏松症制剂、催产药、副交感神经阻断药、拟副交感神经药、前列腺素、心理治疗剂、呼吸制剂、镇静剂、戒烟辅助制剂、交感神经阻断药、震颤制剂、尿道制剂、血管扩张剂、通便药、抗酸剂、离子交换树脂、抗发热药、食欲抑制剂、祛痰药、抗焦虑剂、抗溃疡剂、抗炎物质、冠状动脉扩张剂、脑血管扩张剂、外周血管扩张剂、精神药物、兴奋剂、抗高血压药物、血管收缩药、偏头痛治疗药、抗生素、镇定剂、抗精神病剂、抗肿瘤药、抗凝结剂、抗血栓形成药、催眠药、抗呕吐药、抗呕吐剂、抗惊厥药、神经肌肉药、高血糖和低血糖剂、甲状腺和抗甲状腺制剂、利尿剂、抗痉挛剂、子宫松弛药(terine relaxant)、抗肥胖药、红细胞生成药、抗哮喘药、咳嗽抑制剂、粘液溶解剂、DNA和基因修饰剂,以及它们的组合。
本发明的剂型进一步包括选自味道遮盖制剂、增塑剂、表面活性剂、乳化制剂、增稠剂、粘合剂、冷却剂、唾液刺激剂、甜味剂、抗菌制剂、抗原和它们的组合物的一种或多种成分。
实施例
用于本发明的水溶性膜组合物的制备是使用表1描述的量进行的。
表1
1由ICI American提供
2由OSI提供
3由Pfizer提供,包括麝香草酚(0.064%)、桉油精(0.092%)、甲基水杨酸盐(0.060%)、薄荷醇(0.042%)、水(至多72.8%)、乙醇(26.9%)、安息香酸、波洛沙姆407、安息香酸钠和焦糖色
4由Grain Processing Corporation提供的Pure Cote B792
5由Schering Corporation提供的Claritin(氯雷他定)
6由Hayashibara Biochemical Laboratories,Inc.,Japan提供
7由BASF的Cremophor EL提供
本发明组合物的成分A-J被混合搅拌直至获得均匀混合物。应用真空超过20分钟,开始于500mmHg,在660mmHg直至悬液中所有空气都被移除时结束。该组合物随后使用200微米螺旋绕杆放置在硅酮包被的纸张上和K control Coater Model 101(PK Print Coat Inst.Ltd)。通过在膜底部在90℃加热干燥这些膜。在膜上没有外部的热气流。在约4到6分钟,这些膜被干燥到少于6%的重量百分比的水份。该膜是柔韧的,自持并在膜内提供各种成分的均匀分布。
形成本发明的小袋的各个层可以用各种不同的材料和构造制备。如图6所示,它们自身包括用粘合剂连接压制成的一层或多层。每层可使用各种不同的材料。顶层和底层中每一个包含至少两层的薄片较佳。包含三层的薄片更佳。三层的薄片包括外层16、内层17和中间层18,还包括分布在它们之间的粘合剂15。
一种有效的屏障材料是金属薄片,如铝,它可提供对光线、潮湿和空气的屏障。按照膜需要的屏障和其中包含的各种活性物质,可在各种层次选用其他材料。这些材料包括纸张、聚烯烃,如聚乙烯或聚丙烯、聚酯、水解聚乙烯醋酸盐共聚物和它们的混合物。
如果需要,这些层可包括抗抗静电剂、抗成雾剂、紫外线吸收剂、抗氧化剂、增塑剂、润滑剂、成核剂、分散剂、着色剂、抗真菌剂、抗菌剂、无机填充剂等。
在本发明的一个方面,各层可以通过首先在各层之间涂布粘合剂来压制在一起,随后可共同挤压形成本发明的多层次包装(形式)。粘合剂可包括聚烯烃树脂如用不饱和羧酸或其衍生物的改良物质。不饱和羧酸可包括但不限于丙烯酸、甲基丙烯酸、顺丁烯二酸、反丁烯二酸、丁烯酸、甲叉丁二酸、柠康酸等,以及它们的酯和酐。
图4显示了包含薄片样剂型5的小袋的层次。该小袋包括顶层3和底层4,每个可包含多层压制物质,该小袋如图5所示沿周长封口。这可以通过,例如,加热封口或用粘合剂,如压力敏感性粘合剂,来完成。
产生的小袋也可沿着如图7-9和9a所示的沿着周长的一部分再封口。如图7所示,这可以通过在顶层3和底层4之间用压力敏感性粘合剂在周长的一部分来进行而完成。在沿着周长的该点,顶层和底层可被分开来移出剂型并随后再封口。如图8和9所示,可选择的是,通过沿着顶层3的轨道8和沿着底层4的相应的轨道9在小袋的一部分形成拉链可以在周长的一部分封口和再封口。两条轨道应制备成可以相互衔接,形成沿着周长部分的封口。该轨道的衔接可以用手工压迫,或使用拉链10。图9a中对包装增加了“抗干扰”特征,包括覆盖再封口拉链的材料19的另一层。这可以通过使用粘合剂来贴到顶层3和底层4,或可选择的是在顶层3和底层4的长度上形成另外一层(未显示)。这使得该小袋被消费者打开时首先移开周围层19,在穿孔部分22来使用再封口开口较佳。
在小袋中可包含一个以上的薄片剂型。例如,两个或多个薄片可在顶部相互叠加。如图10所示,一种非水溶性支持膜11,如聚烯烃层,也是薄片形式,可被置于水溶性剂型薄片之间以防止两个或更多薄片的剂量5形式相互粘附。
为了分配剂型,小袋被首先打开。这通过撕扯小袋开口或分离小袋的顶层和底层来进行。薄片可以从小袋中移出,或较佳的是,在顶层和底层分离时,膜与剥脱的小袋顶层和底层分开,这在分配时更容易。在一个实施方案中,小袋顶层和底层从一头剥脱使剂型在直立或垂直位置容易操作。随后,膜/剂型的单位部分可沿着弱化或穿孔的部分撕扯从薄片分离剂量,或其中的部分。薄片的余下部分随后可放回小袋直至将来使用。
虽然本文描述了现在认为是本发明的某些较佳实施方案,本领域熟练技术人员应当知晓在不离开本发明的精神下可进行变化和改进,这些变化和改进是全部落在本发明的真实范围内的。
Claims (17)
1.一种口服剂量输递载体,其含有至少一层可食用膜,所述可食用膜含有活性成分,所述膜含有弱化区域,所述弱化区域将膜分成代表剂量单位的部分,其中活性物质在所述剂量单位中的变化不超过10%。
2.如权利要求1所述的输递载体,其特征在于,还含有额外的一层可食用膜。
3.如权利要求1所述的输递载体,其特征在于,所述弱化区域是穿孔的或有刻痕的。
4.如权利要求1所述的输递载体,其特征在于,所述活性物质是药物或化妆品活性物质。
5.如权利要求1所述的输递载体,其特征在于,所述膜包括基本水溶性材料的载体层。
6.一种用于贮存和分配薄片样速溶剂型的包装,其包括:
a)一个包含顶层和底层的小袋,顶层和底层都有一个外缘,其中,所述顶层和底层在各自的外缘封口以在其中确定一个封闭空间,和
b)一个含在所述封闭空间内的薄片样速溶剂型;其中所述剂型含有至少一层可食用膜和弱化区域,所述弱化区域将膜分成代表剂量单位的部分,其中所述膜含有活性物质,所述活性物质在所述剂量单位中的变化不超过10%。
7.如权利要求6所述的包装,其特征在于,所述弱化区域是穿孔的或有刻痕的。
8.如权利要求6所述的包装,其特征在于,所述小袋是再封口的。
9.一种贮存薄片样速溶剂型的方法,其特征在于,所述方法包括以下步骤:
a)制备薄片样剂型;
其中所述剂型包含至少一层可食用膜,所述可食用膜含有弱化区域,所述弱化区域将膜分成包含在小袋内的代表剂量单位的部分,其中所述膜含有活性物质,所述活性物质在所述剂量单位中的变化不超过10%;
b)制备包含顶层和底层的小袋,所述各层的每一层有围绕所述层外周的边缘;
c)把所述剂型置于所述顶层和底层之间;
d)封闭所述小袋的外缘。
10.一种分配薄片样剂型的方法,包括以下步骤:
a)制备含有活性成分的薄片样剂型;
其中所述剂型包含至少一层可食用膜,所述可食用膜含有弱化区域,所述弱化区域将膜分成包含在小袋内的代表剂量单位的部分,其中活性物质在所述剂量单位中的变化不超过10%;
b)制备包含顶层和底层的小袋,所述各层的每一层有围绕所述层外周的边缘;
c)把所述剂型置于所述顶层和底层之间;
d)可分离地封闭所述小袋的所述边缘部分;
e)打开所述小袋的一部分;
f)沿着所述弱化区域打开所述剂型的一个或多个所述部分;和
g)从所述小袋中移出所述一个或多个剂量单位。
11.如权利要求10所述的方法,还包括再封口所述小袋的步骤。
12.如权利要求10所述的方法,还包括永久性地封闭所述小袋边缘余下部分的步骤。
13.一种小袋,所述小袋包含顶层,所述顶层包含至少两层的薄片;还包含底层,所述底层包含至少两层的薄片,其特征在于,所述小袋沿周长封口,其中至少一层可食用膜含有弱化区域,所述弱化区域将膜分成包含在小袋内的代表剂量单位的部分。
14.一种小袋,包含顶层和底层,其特征在于,所述小袋沿周长的一部分再封口,其中至少一层可食用膜含有弱化区域,所述弱化区域将膜分成包含在小袋内的代表剂量单位的部分。
15.如权利要求14所述的小袋,其特征在于,所述周长的一部分提供压敏粘合剂。
16.如权利要求14所述的小袋,其特征在于,所述周长的一部分可以通过沿顶层形成拉链轨道封口和再封口。
17.如权利要求16所述的小袋,其特征在于,还含有沿着底层的相应的轨道。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39770302P | 2002-07-22 | 2002-07-22 | |
| US60/397,703 | 2002-07-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN03822424.0A Division CN1747656B (zh) | 2002-07-22 | 2003-07-22 | 速溶剂型的包装和分配 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102188409A true CN102188409A (zh) | 2011-09-21 |
Family
ID=30771107
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN03822424.0A Expired - Fee Related CN1747656B (zh) | 2002-07-22 | 2003-07-22 | 速溶剂型的包装和分配 |
| CN201110060549.6A Pending CN102188409A (zh) | 2002-07-22 | 2003-07-22 | 速溶剂型的包装和分配 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN03822424.0A Expired - Fee Related CN1747656B (zh) | 2002-07-22 | 2003-07-22 | 速溶剂型的包装和分配 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20060147493A1 (zh) |
| EP (1) | EP1542903B1 (zh) |
| CN (2) | CN1747656B (zh) |
| AU (1) | AU2003268015A1 (zh) |
| CA (1) | CA2505796C (zh) |
| WO (1) | WO2004009445A2 (zh) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
| US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
| US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
| US6726054B2 (en) | 2002-03-29 | 2004-04-27 | Tapemark | Dispenser package arrangement and methods |
| US8999372B2 (en) * | 2002-11-14 | 2015-04-07 | Cure Pharmaceutical Corporation | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
| US9561182B2 (en) * | 2003-08-22 | 2017-02-07 | Cure Pharmaceutical Corporation | Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals |
| EP1560571A4 (en) * | 2002-11-14 | 2007-11-28 | Innozen Inc | EDIBLE FILM FOR THE RELIEF OF COUGH OR SYMPTOMS ASSOCIATED WITH PHARYNGITIS |
| US20040131662A1 (en) | 2003-11-12 | 2004-07-08 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
| US20040191302A1 (en) | 2003-03-28 | 2004-09-30 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
| US8627828B2 (en) | 2003-11-07 | 2014-01-14 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
| WO2005046363A2 (en) | 2003-11-07 | 2005-05-26 | U.S. Smokeless Tobacco Company | Tobacco compositions |
| JP4547994B2 (ja) * | 2004-06-02 | 2010-09-22 | 救急薬品工業株式会社 | 塊状物質含有積層フィルム状の可食性口腔内投与剤の製造方法および塊状物質含有積層フィルム状の可食性口腔内投与剤 |
| JP5160229B2 (ja) * | 2004-09-30 | 2013-03-13 | モノソル・アールエックス・エルエルシー | 均一の成分を有する多層フィルム |
| US9044049B2 (en) | 2005-04-29 | 2015-06-02 | Philip Morris Usa Inc. | Tobacco pouch product |
| EA012674B1 (ru) | 2005-04-29 | 2009-12-30 | Филип Моррис Продактс С.А. | Табачный продукт в пакетиках |
| WO2006119286A1 (en) * | 2005-05-03 | 2006-11-09 | Innozen, Inc. | Edible film for transmucosal delivery of nutritional supplements |
| US8685478B2 (en) | 2005-11-21 | 2014-04-01 | Philip Morris Usa Inc. | Flavor pouch |
| CN100463674C (zh) * | 2006-12-22 | 2009-02-25 | 江苏奥赛康药业有限公司 | 一种氯雷他定口腔速溶膜及其制备方法 |
| US8616221B2 (en) | 2007-02-28 | 2013-12-31 | Philip Morris Usa Inc. | Oral pouch product with flavored wrapper |
| US9888712B2 (en) | 2007-06-08 | 2018-02-13 | Philip Morris Usa Inc. | Oral pouch products including a liner and tobacco beads |
| US8424541B2 (en) | 2007-07-16 | 2013-04-23 | Philip Morris Usa Inc. | Tobacco-free oral flavor delivery pouch product |
| WO2009010876A2 (en) | 2007-07-16 | 2009-01-22 | Philip Morris Products S.A. | Oral pouch product having soft edge and method of making |
| WO2009010875A2 (en) | 2007-07-16 | 2009-01-22 | Philip Morris Products S.A. | Oral delivery pouch product with coated seam |
| WO2010012470A1 (en) | 2008-07-30 | 2010-02-04 | Research Center Pharmaceutical Engineering Gmbh | A system and method for manufacturing a medication |
| US8377215B2 (en) | 2008-12-18 | 2013-02-19 | Philip Morris Usa Inc. | Moist botanical pouch processing |
| US9027567B2 (en) | 2008-12-30 | 2015-05-12 | Philip Morris Usa Inc. | Oral pouch product with multi-layered pouch wrapper |
| US20100178254A1 (en) * | 2009-01-13 | 2010-07-15 | Monosol Rx Llc | Unit assembly for multiple film dosages, apparatus, and methods |
| US8863755B2 (en) | 2009-02-27 | 2014-10-21 | Philip Morris Usa Inc. | Controlled flavor release tobacco pouch products and methods of making |
| US8747562B2 (en) | 2009-10-09 | 2014-06-10 | Philip Morris Usa Inc. | Tobacco-free pouched product containing flavor beads providing immediate and long lasting flavor release |
| CN102892405A (zh) | 2009-12-28 | 2013-01-23 | 莫诺索尔克斯有限公司 | 包含昂丹司琼的可经口施用的膜剂型 |
| JP5933522B2 (ja) | 2010-03-26 | 2016-06-08 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | タバコポーチ製品の形成に使用するための装置 |
| UA107960C2 (en) | 2010-03-26 | 2015-03-10 | Philip Morris Products Sa | System for distribution of liquid for use in the manufacturing of packaged tobacco products |
| JP6093693B2 (ja) | 2010-04-12 | 2017-03-08 | アルトリア クライアント サービシーズ エルエルシー | 改良したシールを有する袋製品及びその製造方法 |
| US20110290694A1 (en) * | 2010-05-27 | 2011-12-01 | Monosol Rx, Llc | Oral film dosage form having indicia thereon |
| US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
| JPWO2013108384A1 (ja) * | 2012-01-19 | 2015-05-11 | ツキオカフィルム製薬株式会社 | フィルム状歯磨き剤 |
| CN107708429A (zh) * | 2015-04-24 | 2018-02-16 | 国际香料和香精公司 | 递送体系及其制备方法 |
| EP3162364A1 (de) * | 2015-10-28 | 2017-05-03 | LTS LOHMANN Therapie-Systeme AG | Verfahren zur kennzeichnung filmförmiger darreichungsformen |
| KR20190005199A (ko) | 2016-05-05 | 2019-01-15 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| US11229605B2 (en) * | 2017-02-15 | 2022-01-25 | Hewlett-Packard Development Company, L.P. | Printed support structure |
| JP7101671B2 (ja) | 2019-01-15 | 2022-07-15 | ザ プロクター アンド ギャンブル カンパニー | 可撓性かつ溶解性の固体シート物品 |
| WO2020147005A1 (en) * | 2019-01-15 | 2020-07-23 | The Procter & Gamble Company | Multilayer dissolvable solid article with apertures or holes |
| WO2020147010A1 (en) | 2019-01-15 | 2020-07-23 | The Procter & Gamble Company | Multilayer dissolvable solid article with specific aspect ratio |
| US20220331263A1 (en) * | 2019-09-04 | 2022-10-20 | Vitiprints, LLC | Printed Delivery Device Having Supplements |
| US20220304316A1 (en) * | 2021-03-26 | 2022-09-29 | Spellbound Development Group, Inc. | Systems and methods for flavoring and lubricating food items and cooking surfaces |
| US20220304350A1 (en) * | 2021-03-26 | 2022-09-29 | Spellbound Development Group, Inc. | Systems and methods for imparting flavoring and/or lubrication to a surface |
| US12465564B2 (en) | 2021-10-25 | 2025-11-11 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2142537A (en) * | 1936-07-22 | 1939-01-03 | Rare Chemicals Inc | Anesthetic ointment |
| US2277038A (en) * | 1937-10-30 | 1942-03-24 | Curtis David | Anesthetic preparation |
| US2352691A (en) * | 1941-07-25 | 1944-07-04 | Curtis David | Anesthetic compound and preparation |
| US2591544A (en) * | 1949-12-22 | 1952-04-01 | John J Hegarty | Stacking truck |
| NL247796A (zh) * | 1959-01-27 | 1900-01-01 | ||
| US3249109A (en) * | 1963-11-01 | 1966-05-03 | Maeth Harry | Topical dressing |
| GB1142325A (en) * | 1965-05-14 | 1969-02-05 | Higham Stanley Russell | Means for administering drugs |
| US3632740A (en) * | 1968-06-13 | 1972-01-04 | Johnson & Johnson | Topical device for the therapeutic management of dermatological lesions with steroids |
| US3598122A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3640741A (en) * | 1970-02-24 | 1972-02-08 | Hollister Inc | Composition containing gel |
| US3892905A (en) * | 1970-08-12 | 1975-07-01 | Du Pont | Cold water soluble plastic films |
| US3641237A (en) * | 1970-09-30 | 1972-02-08 | Nat Patent Dev Corp | Zero order release constant elution rate drug dosage |
| US3753732A (en) * | 1971-04-19 | 1973-08-21 | Merck & Co Inc | Rapidly disintegrating bakery enrichment wafer |
| US3731683A (en) * | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
| US4251400A (en) * | 1971-11-03 | 1981-02-17 | Borden, Inc. | Hot and cold water redispersible polyvinyl acetate adhesives |
| US3814095A (en) * | 1972-03-24 | 1974-06-04 | H Lubens | Occlusively applied anesthetic patch |
| US4136162A (en) * | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
| US4136145A (en) * | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
| DE2449865B2 (de) | 1974-10-17 | 1981-06-19 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | Folienförmiges Arzneimittel |
| US3972995A (en) * | 1975-04-14 | 1976-08-03 | American Home Products Corporation | Dosage form |
| GB1491272A (en) * | 1975-09-10 | 1977-11-09 | Lingner & Fischer Gmbh | Polymer adhesive compositions containing gelling agents |
| US4031200A (en) * | 1975-12-15 | 1977-06-21 | Hoffmann-La Roche Inc. | Manufacture of pharmaceutical unit dosage forms |
| US4029757A (en) * | 1975-12-15 | 1977-06-14 | Hoffmann-La Roche Inc. | Manufacture of pharmaceutical unit dosage forms |
| US4029758A (en) * | 1975-12-15 | 1977-06-14 | Hoffmann-La Roche Inc. | Preparation of pharmaceutical unit dosage forms |
| US4139627A (en) * | 1977-10-06 | 1979-02-13 | Beecham Inc. | Anesthetic lozenges |
| DE2746414A1 (de) | 1977-10-15 | 1979-04-26 | Gerlach Eduard Chem Fab | Mittel zum dosieren von stoffen und verfahren zu seiner herstellung |
| US4675009A (en) * | 1977-11-07 | 1987-06-23 | Lec Tec Corporation | Drug dispensing device for transdermal delivery of medicaments |
| SE7713618L (sv) * | 1977-12-01 | 1979-06-02 | Astra Laekemedel Ab | Lokalanestetisk blandning |
| SE424955B (sv) * | 1978-06-16 | 1982-08-23 | Hesselgren Sven Gunnar | Retentionspreparat for tandproteser |
| JPS5562012A (en) * | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
| JPS5933361Y2 (ja) * | 1980-03-14 | 1984-09-18 | 日東電工株式会社 | 電極パッド |
| JPS5758615A (en) * | 1980-09-26 | 1982-04-08 | Nippon Soda Co Ltd | Film agnent and its preparation |
| US4503070A (en) * | 1981-07-31 | 1985-03-05 | Eby Iii George A | Method for reducing the duration of the common cold |
| US4432975A (en) * | 1981-04-13 | 1984-02-21 | Icn Pharmaceuticals, Inc. | Process for introducing vitamin B-12 into the bloodstream |
| DE3280021D1 (en) * | 1981-06-12 | 1989-12-21 | Nat Res Dev | Hydrogels |
| US4373036A (en) * | 1981-12-21 | 1983-02-08 | Block Drug Company, Inc. | Denture fixative composition |
| US4460562A (en) * | 1982-01-06 | 1984-07-17 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing propranolol |
| US4451260A (en) * | 1982-03-26 | 1984-05-29 | Minnesota Mining And Manufacturing Company | Sustained release oral medicinal delivery device |
| US4529748A (en) * | 1982-08-16 | 1985-07-16 | Richardson Gmbh | Dental prosthesis adhesive |
| US4608249A (en) * | 1982-11-02 | 1986-08-26 | Nitto Electric Industrial Co., Ltd. | Hydrophilic therapeutic material |
| US4466973A (en) * | 1983-02-01 | 1984-08-21 | Thomas Rennie | Method of treating nasal and sinus congestion |
| JPS59222406A (ja) * | 1983-06-01 | 1984-12-14 | Teijin Ltd | 歯周疾患治療用製剤及びその製造法 |
| US5024701A (en) * | 1983-08-01 | 1991-06-18 | Hercules Incorporated | Denture adhesive composition |
| US4659714A (en) * | 1984-03-27 | 1987-04-21 | Dentsply, Ltd. | Anesthetic methods for mammals |
| CA1248450A (en) * | 1984-04-05 | 1989-01-10 | Kazuo Kigasawa | Soft patch |
| US4740365A (en) * | 1984-04-09 | 1988-04-26 | Toyo Boseki Kabushiki Kaisha | Sustained-release preparation applicable to mucous membrane in oral cavity |
| JPS61502760A (ja) * | 1984-07-24 | 1986-11-27 | キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド | 粘着性経皮投与層 |
| JPS6164570A (ja) * | 1984-09-04 | 1986-04-02 | Akebono Brake Ind Co Ltd | アンチスキツド制御方法 |
| US4593053A (en) * | 1984-12-07 | 1986-06-03 | Medtronic, Inc. | Hydrophilic pressure sensitive biomedical adhesive composition |
| US4748022A (en) * | 1985-03-25 | 1988-05-31 | Busciglio John A | Topical composition |
| US4900556A (en) * | 1985-04-26 | 1990-02-13 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| JPS61280423A (ja) * | 1985-06-05 | 1986-12-11 | Kiyuukiyuu Yakuhin Kogyo Kk | 口腔内粘膜貼付剤 |
| GB8514665D0 (en) * | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
| ES2019275B3 (es) * | 1985-10-09 | 1991-06-16 | Desitin Arzneimittel Gmbh | Metodo para la produccion de una forma de administracion y de dosificacion para farmacos reactivos u otros principios activos. |
| US5229164A (en) * | 1985-12-19 | 1993-07-20 | Capsoid Pharma Gmbh | Process for producing individually dosed administration forms |
| JPH0759496B2 (ja) * | 1986-03-25 | 1995-06-28 | ロ−ト製薬株式会社 | 歯周病治療剤 |
| US4722761A (en) * | 1986-03-28 | 1988-02-02 | Baxter Travenol Laboratories, Inc. | Method of making a medical electrode |
| IL78826A (en) * | 1986-05-19 | 1991-05-12 | Yissum Res Dev Co | Precursor composition for the preparation of a biodegradable implant for the sustained release of an active material and such implants prepared therefrom |
| DE3630603A1 (de) | 1986-09-09 | 1988-03-10 | Desitin Arzneimittel Gmbh | Darreichungs- und dosierungsform fuer arzneimittelwirkstoffe, reagentien oder dergleichen sowie verfahren zu deren herstellung |
| JPH0739508B2 (ja) * | 1986-11-11 | 1995-05-01 | 株式会社林原生物化学研究所 | プルラン・ポリエチレングリコ−ル会合物とその製造方法並びに用途 |
| JPH0744940B2 (ja) * | 1986-12-24 | 1995-05-17 | ライオン株式会社 | 口腔貼付用基材 |
| US4860754A (en) * | 1987-04-01 | 1989-08-29 | E. R. Squibb & Sons, Inc. | Electrically conductive adhesive materials |
| US5028632A (en) * | 1987-04-20 | 1991-07-02 | Fuisz Pharmaceutical Ltd. | Taste masked medicated pharmaceutical |
| DE3714074A1 (de) * | 1987-04-28 | 1988-11-10 | Hoechst Ag | Grundlage fuer schleimhaut- und prothesenhaft-pasten, verfahren zu ihrer herstellung sowie pasten auf basis dieser grundlage |
| DE3726797A1 (de) * | 1987-08-12 | 1989-02-23 | Bayer Ag | Arzneimittel fuer den bereich der mundhoehle |
| US4927634A (en) * | 1987-12-16 | 1990-05-22 | Richardson-Vicks Inc. | Pharmaceutical compositions containing dyclonine HC1 and phenol |
| US4915950A (en) * | 1988-02-12 | 1990-04-10 | Cygnus Research Corporation | Printed transdermal drug delivery device |
| US5234957A (en) * | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US4900552A (en) * | 1988-03-30 | 1990-02-13 | Watson Laboratories, Inc. | Mucoadhesive buccal dosage forms |
| US4937078A (en) * | 1988-08-26 | 1990-06-26 | Mezei Associates Limited | Liposomal local anesthetic and analgesic products |
| US4948580A (en) * | 1988-12-08 | 1990-08-14 | E. R. Squibb & Sons, Inc. | Muco-bioadhesive composition |
| US4910247A (en) * | 1989-03-27 | 1990-03-20 | Gaf Chemicals Corporation | Adhesive composition |
| JPH02258718A (ja) * | 1989-03-31 | 1990-10-19 | Nippon Kayaku Co Ltd | ペースト状基剤及び製剤 |
| US5089307A (en) * | 1989-05-23 | 1992-02-18 | Mitsubishi Rayon Co., Ltd. | Edible film and method of making same |
| JPH03232817A (ja) * | 1990-02-07 | 1991-10-16 | Showa Yakuhin Kako Kk | 貼付剤 |
| DE4018247A1 (de) * | 1990-06-07 | 1991-12-12 | Lohmann Therapie Syst Lts | Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen |
| US5111945A (en) * | 1991-09-13 | 1992-05-12 | Kidde Industries, Inc. | Boom extension alignment device |
| JP3232488B2 (ja) * | 1992-08-20 | 2001-11-26 | 株式会社林原生物化学研究所 | プルラン高含有物とその製造方法並びに用途 |
| US5614212A (en) * | 1992-04-08 | 1997-03-25 | International Medical Associates, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
| US6024975A (en) * | 1992-04-08 | 2000-02-15 | Americare International Diagnostics, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
| US5286502A (en) * | 1992-04-21 | 1994-02-15 | Wm. Wrigley Jr. Company | Use of edible film to prolong chewing gum shelf life |
| US5393528A (en) * | 1992-05-07 | 1995-02-28 | Staab; Robert J. | Dissolvable device for contraception or delivery of medication |
| US5411945A (en) * | 1992-08-29 | 1995-05-02 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Pullulan binder and its uses |
| US5605696A (en) * | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
| US5891461A (en) * | 1995-09-14 | 1999-04-06 | Cygnus, Inc. | Transdermal administration of olanzapine |
| US5766620A (en) * | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
| EP0890068A1 (en) * | 1996-03-29 | 1999-01-13 | Minnesota Mining And Manufacturing Company | Apparatus and method for drying a coating on a substrate employing multiple drying subzones |
| US5800832A (en) * | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
| US20010006677A1 (en) * | 1996-10-29 | 2001-07-05 | Mcginity James W. | Effervescence polymeric film drug delivery system |
| DE19646392A1 (de) * | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
| US5806284A (en) | 1997-03-03 | 1998-09-15 | Apothecus Pharmaceutical Corp. | Method and system for producing sealed packages of a film which is dissolved in a body fluid |
| US20050048102A1 (en) * | 1997-10-16 | 2005-03-03 | Virotex Corporation | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| DE19800682B4 (de) * | 1998-01-10 | 2004-07-08 | Lts Lohmann Therapie-Systeme Ag | Verfahren zur Herstellung einer Primärverpackung für film- oder oblatenförmige Darreichungsformen |
| US6072100A (en) * | 1998-01-28 | 2000-06-06 | Johnson & Johnson Consumer Products, Inc. | Extrudable compositions for topical or transdermal drug delivery |
| US6103266A (en) * | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
| US6287595B1 (en) * | 1998-06-10 | 2001-09-11 | Delsys Pharmaceuticals Corporation | Biomedical assay device |
| US6596298B2 (en) | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
| US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| US6231957B1 (en) * | 1999-05-06 | 2001-05-15 | Horst G. Zerbe | Rapidly disintegrating flavor wafer for flavor enrichment |
| US20020076440A1 (en) * | 1999-06-25 | 2002-06-20 | Thomas Leon | Veterinary delivery systems and methods of delivering effective agents to animals |
| US20030124176A1 (en) * | 1999-12-16 | 2003-07-03 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| GB0006432D0 (en) * | 2000-03-17 | 2000-05-03 | Stanelco Fibre Optics Ltd | Capsules |
| US7067116B1 (en) * | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
| US6660292B2 (en) * | 2001-06-19 | 2003-12-09 | Hf Flavoring Technology Llp | Rapidly disintegrating flavored film for precooked foods |
| US6656493B2 (en) * | 2001-07-30 | 2003-12-02 | Wm. Wrigley Jr. Company | Edible film formulations containing maltodextrin |
| US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US20040096569A1 (en) * | 2002-11-15 | 2004-05-20 | Barkalow David G. | Edible film products and methods of making same |
| US7470397B2 (en) * | 2003-10-24 | 2008-12-30 | Adhesives Research, Inc. | Disintegratable films for diagnostic devices |
| AU2006326377B2 (en) * | 2005-12-13 | 2010-10-07 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
-
2003
- 2003-07-22 CA CA2505796A patent/CA2505796C/en not_active Expired - Lifetime
- 2003-07-22 EP EP03748966.3A patent/EP1542903B1/en not_active Revoked
- 2003-07-22 CN CN03822424.0A patent/CN1747656B/zh not_active Expired - Fee Related
- 2003-07-22 AU AU2003268015A patent/AU2003268015A1/en not_active Abandoned
- 2003-07-22 US US10/521,823 patent/US20060147493A1/en not_active Abandoned
- 2003-07-22 WO PCT/US2003/022882 patent/WO2004009445A2/en not_active Ceased
- 2003-07-22 CN CN201110060549.6A patent/CN102188409A/zh active Pending
-
2014
- 2014-04-14 US US14/252,396 patent/US20140305835A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1747656A (zh) | 2006-03-15 |
| CA2505796A1 (en) | 2004-01-29 |
| WO2004009445A3 (en) | 2004-06-10 |
| WO2004009445A2 (en) | 2004-01-29 |
| CN1747656B (zh) | 2011-05-04 |
| EP1542903B1 (en) | 2015-05-20 |
| US20140305835A1 (en) | 2014-10-16 |
| US20060147493A1 (en) | 2006-07-06 |
| EP1542903A2 (en) | 2005-06-22 |
| EP1542903A4 (en) | 2009-08-12 |
| AU2003268015A8 (en) | 2004-02-09 |
| CA2505796C (en) | 2012-01-03 |
| WO2004009445A9 (en) | 2004-04-01 |
| AU2003268015A1 (en) | 2004-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102188409A (zh) | 速溶剂型的包装和分配 | |
| JP2620789B2 (ja) | 活性物質の経口投与製剤 | |
| KR100627199B1 (ko) | 점막 전달용 조성물 및 방법 | |
| CA2476250C (en) | Drug dose-form and method of manufacture | |
| JP5538905B2 (ja) | ポリマーを主成分とするフィルムおよびこれから製造した薬物放出系 | |
| EP1980245A1 (en) | Bilayer lyophilized pharmaceutical compositions and methods of making and using same | |
| AU2007352009B2 (en) | Process for producing preparation for oral administration | |
| CN101534803A (zh) | 给予含有药物的薄膜产品的方法 | |
| US20090047350A1 (en) | Perforated water soluble polymer based edible films | |
| CN108175762A (zh) | 用于直接在包装表面上形成药用产品的方法和系统 | |
| CN102670568A (zh) | 基于聚氧乙烯的薄膜及由其制造的药物传递系统 | |
| IL168606A (en) | Sheet like dosage form for releasing nicotine in the oral or nasal cavity | |
| JP2009507854A (ja) | 粘着防止剤を組み込む即溶性製剤用の均一なフィルム | |
| US20100080829A1 (en) | Lyophilized pharmaceutical compositions and methods of making and using same | |
| JPH07502736A (ja) | 親水性巨大分子からなる骨格を有する作用物質含有固形物およびその調製法 | |
| US20220008330A1 (en) | Method and System for Manufacturing Oral Soluble Films, Compositions of Oral Soluble Films, Oral Soluble Films Made by Thereby, and Methods of Use Thereof | |
| EP2152234A1 (en) | Lyophilized pharmaceutical compositions and methods of making and using same | |
| JPS58213709A (ja) | 歯肉粘膜用貼付剤 | |
| WO2022178279A1 (en) | Method and system for manufacturing oral soluble films, compositions of oral soluble films, oral soluble films made by thereby, and methods of use thereof | |
| US20230255896A1 (en) | Method and system for manufacturing oral soluble films, compositions of oral soluble films, oral soluble films made by thereby, and methods of use thereof | |
| JP2009521532A (ja) | 活性物質を放出するための、pH調節されたフィルム | |
| WO2005000191A1 (ja) | フィルム状口腔内投与剤の打ち抜き成型方法および打ち抜き成型装置 | |
| Whiteman | Oral Films | |
| WO2026021397A1 (zh) | 膜剂产品和口用膜产品 | |
| JP2000186032A (ja) | 易崩壊性固形物およびその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110921 |